Streetbeat News

Analyst Ratings

TMDX

JP Morgan analyst Allen Gong maintains an Overweight rating on TransMedics Group (TMDX) and raises the price target from $87 to $105.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:13 pm

MELI

JP Morgan analyst Marcelo Santos has maintained an Overweight rating on MercadoLibre (NASDAQ:MELI) and increased the price target from $2000 to $2150.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:10 pm

HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) reported better-than-expected Q4 earnings, beating analyst estimates with earnings of 1 cent per share and quarterly sales of $246.62 million. The company also issued strong guidance for Q1 2024 and FY 2024, expecting to surpass $1 billion in revenue. Following the report, HIMS shares surged 31.9% to $13.52. Analysts from Truist Securities, Piper Sandler, Citigroup, and Guggenheim have subsequently raised their price targets on HIMS.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 6:10 pm

FRPT

JP Morgan analyst Ken Goldman has maintained a Neutral rating on Freshpet (NASDAQ:FRPT) and increased the price target from $67 to $102.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:08 pm

ALB

Albemarle's stock price increased following Mizuho's decision to maintain a Neutral rating while raising its price target from $105 to $115.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:07 pm

FIS

JP Morgan analyst Tien-Tsin Huang maintains an Overweight rating on Fidelity National Info (FIS) and raises the price target from $71 to $75.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:06 pm

EVER

JP Morgan analyst Cory Carpenter has maintained an Overweight rating on EverQuote (NASDAQ:EVER) and increased the price target from $13 to $25.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:05 pm

EDIT

JP Morgan analyst Brian Cheng has maintained a Neutral rating on Editas Medicine (NASDAQ:EDIT) and raised the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:02 pm

CVX

Financial analysis of Chevron's (NYSE:CVX) options market reveals a bearish sentiment among traders, with 57% showing bearish tendencies. The analysis predicts a price range of $130.0 to $170.0 for Chevron, based on unusual trade activity and options volume and interest. Noteworthy options activity includes both bearish and bullish trades with expiration dates ranging from April 2024 to July 2024. Chevron, a major integrated energy company, has seen its stock price decrease by -0.6%, with a current price of $153.53. Industry analysts have set an average target price of $175.0, with opinions varying from Outperform to Hold.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:00 pm

COGT

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Cogent Biosciences (NASDAQ:COGT) and increased the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:00 pm